We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+8.59%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$102M
AUM Growth
-$835K
Cap. Flow
-$2.14M
Cap. Flow %
-2.1%
Top 10 Hldgs %
58.99%
Holding
87
New
21
Increased
24
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$4.68M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.45M
3
ARDX icon
Ardelyx
ARDX
+$2.29M
4
ALMS
Alumis Inc
ALMS
+$1.65M
5
ITOS
iTeos Therapeutics
ITOS
+$1.61M

Top Sells

Rank Stock Value
1
OPTN
OptiNose
OPTN
+$7.23M
2
URGN icon
UroGen Pharma
URGN
+$3.69M
3
AQST icon
Aquestive Therapeutics
AQST
+$3.04M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.36M
5
ESTA icon
Establishment Labs
ESTA
+$2.35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYO icon
26
Myomo
MYO
$38.6M
$988K 0.97%
457,419
+180,712
+65% +$655K
RZLT icon
27
Rezolute
RZLT
$473M
$977K 0.96%
+219,000
New +$813K
XERS icon
28
Xeris Biopharma Holdings
XERS
$1.41B
$958K 0.94%
205,100
+102,835
+101% +$471K
PMVP icon
29
PMV Pharmaceuticals
PMVP
$59.2M
$897K 0.88%
845,968
+215,785
+34% +$212K
SNDX icon
30
Syndax Pharmaceuticals
SNDX
$1.73B
$870K 0.85%
+92,900
New +$1.02M
GRCE
31
Grace Therapeutics
GRCE
$36M
$869K 0.85%
292,500
-2,050
-0.7% -$5.46K
KZR
32
DELISTED
Kezar Life Sciences
KZR
$778K 0.76%
169,859
+69,859
+70% +$299K
ANGO icon
33
AngioDynamics
ANGO
$589M
$765K 0.75%
+77,141
New +$755K
ACHV icon
34
Achieve Life Sciences
ACHV
$618M
$753K 0.74%
+333,333
New +$949K
ACRS icon
35
Aclaris Therapeutics
ACRS
$739M
$698K 0.68%
491,300
-36,542
-7% -$49.4K
VIR icon
36
Vir Biotechnology
VIR
$1.45B
$655K 0.64%
130,000
-14,628
-10% -$78.4K
BIOA
37
BioAge Labs
BIOA
$934M
$624K 0.61%
151,085
+101,085
+202% +$407K
LQDA icon
38
Liquidia Corp
LQDA
$7.49B
$623K 0.61%
+50,000
New +$740K
ANTX icon
39
AN2 Therapeutics
ANTX
$175M
$577K 0.57%
+544,494
New +$649K
KPRX icon
40
Kiora Pharmaceuticals
KPRX
$11.1M
$513K 0.5%
178,000
-22,647
-11% -$69K
SPRO icon
41
Spero Therapeutics
SPRO
$69.5M
$455K 0.45%
+156,888
New +$226K
HLVX
42
DELISTED
HilleVax
HLVX
$450K 0.44%
226,009
-12,941
-5% -$23.7K
THTX
43
DELISTED
Theratechnologies
THTX
$446K 0.44%
189,051
+163,226
+632% +$400K
VSTM icon
44
CALL
Verastem
VSTM
$539M
$415K 0.41%
+100,000
New +$626K
LUNG icon
45
Pulmonx
LUNG
$53.6M
$378K 0.37%
+145,900
New +$576K
HCAT icon
46
Health Catalyst
HCAT
$157M
$377K 0.37%
+100,000
New +$393K
ESTA icon
47
Establishment Labs
ESTA
$2.77B
$299K 0.29%
7,000
-67,500
-91% -$2.35M
DVAX
48
DELISTED
Dynavax Technologies
DVAX
$298K 0.29%
+30,000
New +$316K
ABEO icon
49
Abeona Therapeutics
ABEO
$337M
$256K 0.25%
+45,000
New +$256K
SVRA icon
50
Savara
SVRA
$1.08B
$194K 0.19%
85,000
+55,921
+192% +$152K
1
2
3 4

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Stonepine Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Stonepine Capital Management held 87 positions worth $102M, down 0.81% from $103M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Stonepine Capital Management's Q2 2025 filing shows 21 new, 24 increased, 14 reduced and 28 closed positions. Its largest new stake was Ardelyx: 555,000 shares worth $2.18M. The largest sale was OptiNose, an estimated $7.23M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2025 buy was Ardelyx: 555,000 shares worth $2.18M.
  • Stonepine Capital Management added most to Verastem in Q2 2025, an estimated $4.68M increase.
  • Stonepine Capital Management's biggest Q2 2025 reduction was Establishment Labs, cutting an estimated $2.35M.
  • Stonepine Capital Management fully exited OptiNose in Q2 2025, selling an estimated $7.23M.
  • Stonepine Capital Management's ten largest holdings make up 59% of its $102M portfolio in Q2 2025.
  • Stonepine Capital Management opened 21 new positions and closed 28 in Q2 2025.
  • Stonepine Capital Management's portfolio value fell 0.81% quarter-over-quarter to $102M.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.